Prostate Cancer - Results from #2100

European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. September 26, 2023

The Highest Grade Group Does Not Drive the Risk of Recurrence when Systematic and Multiparametric Magnetic Resonance Imaging (MRI)-targeted Biopsies are Discordant: Preliminary Findings Using Radical Prostatectomy Pathology as a Surrogate for MRI-targeted September 26, 2023

Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling. September 26, 2023

Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO). September 26, 2023

Assessing cancer risk in the anterior part of the prostate using micro-ultrasound: validation of a novel distinct protocol. September 26, 2023

Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial. September 25, 2023

Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer. September 25, 2023

The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. September 25, 2023

Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. September 25, 2023

Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer. September 25, 2023

Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. September 25, 2023

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers. September 25, 2023

Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis. September 25, 2023

A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling. September 25, 2023

Circulating trans fatty acids are associated with prostate cancer in Ghanaian and American men. September 25, 2023

Exploring the Association Between Online Health Information and Racial Disparities in Prostate Cancer. September 25, 2023

A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma. September 25, 2023

Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. September 25, 2023

Alterations in the Epigenetic Machinery Associated with Prostate Cancer Health Disparities. September 25, 2023

LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function. September 25, 2023

Page 106 of 1439